

# Genomic insights into colistin resistance evolution in *Pseudomonas Aeruginosa*

Nguyen Bao Vy Tran<sup>1,2</sup>, Anh Tu Mai<sup>1,2</sup>, Nhat Thong Le<sup>1,2,3</sup>, Thuc Quyen Huynh<sup>1,2,3</sup>, Minh Thiet Vu<sup>4</sup>, Minh Thong Le<sup>1,2</sup>, Thi Thu Hoai Nguyen<sup>1,2,3,\*</sup>



Use your smartphone to scan this QR code and download this article

<sup>1</sup>School of Biotechnology, International University, Ho Chi Minh City 70000, Vietnam.

<sup>2</sup>Vietnam National University, Ho Chi Minh City 70000, Vietnam.

<sup>3</sup>Research Center for Infectious Diseases, International University, Vietnam.

<sup>4</sup>NTT Hi-Tech Institute, Nguyen Tat Thanh University, Vietnam.

## Correspondence

**Thi Thu Hoai Nguyen**, School of Biotechnology, International University, Ho Chi Minh City 70000, Vietnam.

Vietnam National University, Ho Chi Minh City 70000, Vietnam.

Research Center for Infectious Diseases, International University, Vietnam.

Email: ntthoai@hcmiu.edu.vn

## History


- Received: 2024-05-17
- Accepted: 2024-06-27
- Published Online: 2024-xx-xx

DOI :



## ABSTRACT

Colistin (polymyxin E) is the last-resort antibiotic used to treat multidrug-resistant Gram-negative bacterial infections, including those caused by *Pseudomonas aeruginosa*. The global emergence of colistin-resistant *Pseudomonas aeruginosa* is a significant concern for healthcare professionals. Therefore, identifying key contributors to the development of colistin resistance is crucial for addressing this issue. In this study, *P. aeruginosa* ATCC 9027 was serially exposed to subminimal inhibitory concentrations (MICs) of colistin for 14 consecutive days to obtain the Col-E1 strain. The Col-E1 strain was then cultured for 10 days in antibiotic-free medium to acquire the Col-E2 strain. The whole-genome sequences of three strains, namely, *P. aeruginosa* ATCC 9027 (the original strain, PA-1), Col-E1 and Col-E2, were assembled, annotated and analyzed. The bioinformatics pipeline included FASTQC (v0.11.9) for quality control; Unicycler (v.0.5.0) for *de novo* assembly; Bowtie2 (v2.4.5) and Picard Tools (v.2.27.4) for alignment; SAMtools (v1.11) and BCFtools (v.1.15) for variant calling; and SnpEff (v5.1) for variant annotation. As a result, we obtained a draft genome of *P. aeruginosa* ATCC 9027 consisting of 6,314,207 bp with 146-fold coverage. After aligning Col-E1 and Col-E2 against the draft genome, the number of insertion-deletions (INDELs) and single nucleotide polymorphisms (SNPs) were found, with 486 INDELs and 162 SNPs for Col-E1 and 474 INDELs and 163 SNPs for Col-E2. A high overlap rate of variants, including 448 INDELs and 153 SNPs, was observed between Col-E1 and Col-E2, indicating that the number of variants was constant. The analysis revealed notable mutations in genes encoding ribosomal components (*rpsL*, *rpsG*, and *rpsJ*), genes involved in efflux transmembrane transporter activity (*czcA\_1*), and genes encoding an outer membrane porin (*oprD*). The variants were found in upstream (36.5%), downstream (25.7%) or intergenic (19.1%) regions. These mutations may be involved in gene expression regulation, leading to the development of a colistin-resistant phenotype. In conclusion, this study provided a preliminary overview of how *P. aeruginosa* responds to colistin antibiotic stress at the genomic level. These mutations could be used as markers for colistin resistance and further investigated to clarify their role in the colistin resistance of *Pseudomonas aeruginosa*.



## Genomic alterations of *P. aeruginosa* ATCC 9027 under colistin exposure.

**Key words:** Antibiotic resistance, colistin, *Pseudomonas aeruginosa*, whole-genome analysis

**Cite this article :** Tran N B V, Mai A T, Le N T, Huynh T Q, Vu M T, Le M T, Nguyen T T H. **Genomic insights into colistin resistance evolution in *Pseudomonas Aeruginosa*.** *Sci. Tech. Dev. J.* 2024; ():1-10.

## Copyright

© VNUHCM Press. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.



## 1 INTRODUCTION

*Pseudomonas aeruginosa* (*P. aeruginosa*) is a gram-negative, rod-shaped bacterium that usually causes chronic infections. Due to its ability to adapt and survive under various environmental and physical conditions, *P. aeruginosa* is among the group of six bacteria known as “ESKAPE” pathogens and is considered a priority by the World Health Organization due to its antibiotic resistance<sup>1</sup>. In some cases, colistin is the only effective treatment for *P. aeruginosa* resistant to all tested antibiotics<sup>2</sup>. Colistin (polymyxin E) is an effective antimicrobial agent against gram-negative bacterial infections. However, it is often used as a last-resort treatment for *P. aeruginosa* infections caused by multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains<sup>3</sup>. Colistin primarily acts on the outer membrane of gram-negative bacteria. It works by binding to the phosphate groups of membrane lipids and replacing divalent cations ( $\text{Ca}^{2+}$  and  $\text{Mg}^{2+}$ ). This process disrupts the integrity of the outer membrane and increases its permeability, causing the release of intracellular contents and ultimately leading to cell death<sup>4,5</sup>. Resistance to colistin occurs with lipopolysaccharide (LPS) modification through different routes. The most common strategies for overcoming colistin resistance are modifications of the bacterial outer membrane through the alteration of LPS and a reduction in its negative charge<sup>6,7</sup>. The other strategy is the overexpression of efflux pump systems<sup>8</sup>. Another mechanism is the overproduction of capsule polysaccharides<sup>9</sup>. In this study, whole-genome analysis using Illumina short-read sequencing and bioinformatic tools was carried out to assist in the characterization of antibiotic resistance. This study was the first in Vietnam to construct a full genome assembly of *P. aeruginosa* ATCC 9027 and analyze the genetic mutations caused by colistin exposure. By aligning the genomic sequences of colistin-exposed *P. aeruginosa* strains to those of the original strain before exposure, potential mutations that can be used as markers for colistin resistance could be identified, and how *P. aeruginosa* underwent microevolution to survive antibiotic stress could be determined. With the emergence of colistin-resistant *P. aeruginosa* worldwide, a study on the development of colistin resistance in *P. aeruginosa* could be the key to controlling the spread of resistance.

## 48 MATERIALS AND METHODS

### 49 Bacterial strains

*P. aeruginosa* ATCC 9027 was used as the original strain (PA-1). Strains Col-E1 and Col-E2 were obtained from *P. aeruginosa* ATCC 9027. In brief, *P.*

*aeruginosa* ATCC 9027 (colistin MIC= 4  $\mu\text{g}/\text{ml}$ ) was cultured in sub-MICs of colistin for 14 days to obtain Col-E1 (colistin MIC = 16  $\mu\text{g}/\text{ml}$ ). Col-E2 (colistin MIC = 8  $\mu\text{g}/\text{ml}$ ) was obtained after culturing Col-E1 in colistin-free medium for 10 days. The duration was selected on day 14 for exposure and 10 for reversion because they are the time points at which the MIC values of the strains became stable. All bacterial strains were stored at  $-80^\circ\text{C}$  in Tryptic Soya broth (TSB; HiMedia) supplemented with 30 % glycerol (TSB/glycerol 7: 3, v/v). For genomic DNA extraction, the samples were thawed directly from storage and cultured at  $37^\circ\text{C}$  overnight at 120 rounds/minute (rpm) in TSB.

### DNA isolation and whole-genome sequencing

Genomic DNA was extracted using a GeneJET Genomic DNA Purification Kit (Thermo Fisher Scientific). Total DNA was quantified using a BioTek Take3 (Agilent Technologies, Santa Clara, CA, USA). The paired-end (PE) libraries were prepared using the NEBNext Ultra II DNA Library Prep Kit for Illumina (New England BioLabs, USA) according to the manufacturer's instructions. Finally, the paired-end libraries ( $2 \times 150$  bp) were sequenced on an Illumina MiniSeq system at KTest Science Co., Ltd. (Vietnam). The raw sequences were deposited in the NCBI BioProject under accession number PRJNA1111315.

### De novo assembly and sequence annotation

The PA-1 strain was used as a reference strain. The low-quality bases and adapter sequences were removed using Cutadapt (version 4.1)<sup>10</sup>. Sequence quality was evaluated using FastQC (v0.12.1)<sup>11</sup>. High-quality reads of PA-1 were then assembled by the hybrid assembly pipeline Unicycler (v0.5.0), which yields accurate, comprehensive, and cost-effective data<sup>12</sup>. After that, the assembly was evaluated using QUAST (v5.2.0)<sup>13</sup>. Prokka (v1.14.5) was used to annotate the draft genome of PA-1<sup>14</sup>.

### WGS sequencing analyses, processing, and variant calling and annotation

The raw sequence reads of Col-E1 and Col-E2 were also subjected to the QC process as described above. High-quality reads were mapped against the draft genome using Bowtie2 (v2.4.5)<sup>15</sup> with parameters specifying for paired-end reads followed by mark duplication using Picard tools (v2.27.4). The alignment files were then sorted and indexed using SAMtools

(v1.11)<sup>16</sup>. Qualimap (v2.2.1) was used for evaluating sequence alignment data<sup>17</sup>. The SAMtools mpileup utility and BCFtools (v1.15) were used to call genomic variants. Hard filtering was then applied to the raw variant data to extract high-confidence mutations. High-confidence variants were subjected to SNPeff (v5.0e)<sup>18</sup> for gene-based and region-based annotation.

The workflow of the study is summarized in Figure 1.

## 111 RESULTS

### 112 Draft genome sequence of *Pseudomonas aeruginosa* ATCC 9027.

114 After removing low-quality reads, 6,317,853 paired-end reads were retained, with an average quality per read of 36. A 6,314,207-bp assembly with 146-fold coverage was constructed consisting of 79 contigs ranging from 200 bases to 479,350 total bases in length (Figure 2A, B). The assembled N50 value was 284,316 bp, and the average GC content was 66.66% (Figure 2C). After draft genome annotation, 5980 genes were identified. The sequences ranged from 28 bp to 13,029 bp, including 5811 coding sequences, 99 miscellaneous RNAs, 69 tRNAs, and 1 CRISPR molecule.

### 126 Genomic variation of colistin-resistant *Pseudomonas aeruginosa*

128 The genomic alteration of *P. aeruginosa* in response to colistin was revealed by aligning both Col-E1 and Col-E2 against the PA-1 draft genome. High-quality mapping reads were obtained with 6,657,709 reads for Col-E1 and 7,717,242 reads for Col-E2. The mean depth coverages were 155.46-fold greater for Col-E1 and 181.52-fold greater for Col-E2, with a similar mapping rate of 99.38%.

136 After hard filtering, 162 and 486 high-confidence SNPs and INDELS were identified in Col-E1, while 163 and 474 high-confidence SNPs and INDELS were identified in Col-E2 (Figure 3A). A high overlap rate of variants between Col-E1 and Col-E2 was observed, including 153 SNPs and 448 INDELS (Figure 3B, C). This observation indicated that colistin exposure has a permanent effect on genomic alterations. Further investigations are necessary to reach a definitive conclusion.

### 146 Functional annotation of genomic variants.

147 The functional annotation of the genomic variants is summarized in Table 1 and visualized in Figure 4 and Figure 5. In Col-E1, genomic alterations resulted in 2,693 functional effects, including

45 (1.67%) LOW, 37 (14%) MODERATE, 17 (0.63%) HIGH, and 2,594 (96.32%) MODIFIER. Among the HIGH effect variants, 2 stop\_gain variants related to 2 SNPs at the ATCC\_9027\_59700\_gene (p.Gln419\*) and ATCC\_9027\_59770\_gene (p.Arg65\*) loci were identified. Most INDELS caused frameshift mutations<sup>14</sup>, and 4 INDELS were related to start\_lost mutations (Figure 4, Table 1). These mutations are located in *puuA* and *aroH*, which are not known to cause antibiotic resistance.

A high number of alterations were found to have a MODIFIER effect (Table 1). Notable genes included ribosomal components (*rpsL*, *rpsG*, and *rpsJ*), efflux transmembrane transporter activity (*czcC\_1*), and the outer membrane porin *oprD*. An insertion mutation upstream of *oprD*, which encodes an outer membrane porin that plays a significant role in the uptake of basic amino acids and carbapenems, was detected.

As expected, the variant profile of Col-E2 was similar to that of Col-E1 (Figure 5, Table 1).

## DISCUSSION

This study is the first in Vietnam to provide a whole-genome assembly of *P. aeruginosa* ATCC 9027 and characterize the genomic changes under colistin antibiotic stress. It has been suggested that antibiotics at low doses tend to increase the mutation rate in pathogens. The hypothesis is that higher mutation rates enable faster adaptation to specific environments<sup>19,20</sup>. Exposure to antibiotics has been shown to increase mutation and recombination frequencies in bacteria through the SOS response, even under sub-MIC conditions, which do not completely inhibit bacterial growth<sup>20,21</sup>. Although the mechanism of polymyxin resistance is relatively well characterized<sup>22</sup>, there have not been many reports on genomic changes under sub-MIC antibiotic pressure. Thus, this article provides a preliminary overview of how the *P. aeruginosa* genome responds to colistin antibiotic stress. The genomic profiles of Col-E1 and Col-E2 were similar, indicating that consistent genomic changes resulted in a resistance phenotype in both strains. However, the specific genomic variations that lead to the development of colistin resistance are still unclear.

As a last resort antibiotic, there are considerably fewer reports of colistin resistance compared to other antibiotics or polymyxins in general. The most common chromosome-encoded mechanisms of polymyxin involve mutations in two-component systems (TCSs), namely, *PmrA/PmrB*, *PhoP/PhoQ*, *ParR/ParS*, *ColR/ColS* and *CprR/CprS*, which results in the activation and overexpression of LPS-modifying genes<sup>22</sup>. Among these, mutations in

**Table 1: Functional annotation of Col-E1 and Col-E2.**

Sample	Type	Impact	Region Annotation	Count	Percent (%)		
Col-E1	SNPs	LOW	synonymous_variant	45	1.67		
		MODERATE	missense_variant	27	1		
		HIGH	stop_gained	2	0.07		
		MODIFIER	downstream_gene_variant	133	4.94		
		MODIFIER	intergenic_region	88	3.27		
		MODIFIER	upstream_gene_variant	235	8.73		
	INDELS	MODERATE	conservative_inframe_deletion	1	0.04		
		MODERATE	conservative_inframe_insertion	3	0.11		
		MODERATE	disruptive_inframe_insertion	6	0.22		
		HIGH	frameshift_variant	14	0.52		
		HIGH	frameshift_variant&start_lost	1	0.04		
		MODIFIER	downstream_gene_variant	572	21.24		
		MODIFIER	feature_elongation	412	15.3		
		MODIFIER	intergenic_region	433	16.08		
		MODIFIER	upstream_gene_variant	721	26.77		
		Col-E2	SNPs	LOW	synonymous_variant	45	1.66
				MODERATE	missense_variant	26	0.96
				HIGH	stop_gained	2	0.07
MODIFIER	downstream_gene_variant			161	5.93		
MODIFIER	intergenic_region			90	3.31		
MODIFIER	upstream_gene_variant			264	9.72		
INDELS	MODERATE		conservative_inframe_deletion	1	0.04		
	MODERATE		conservative_inframe_insertion	2	0.07		
	MODERATE		disruptive_inframe_deletion	1	0.04		
	MODERATE		disruptive_inframe_insertion	5	0.18		
	HIGH		frameshift_variant	13	0.48		
	MODIFIER		downstream_gene_variant	526	19.36		
	MODIFIER		feature_elongation	402	14.8		
	MODIFIER		intergenic_region	423	15.57		
	MODIFIER		upstream_gene_variant	756	27.82		





Figure 1: Workflow of the study.

204 *pmrA*, *pmrB* and *phoQ* have been reported in colistin-  
205 resistant clinical isolates<sup>23</sup>.

206 In this study, no common mutations were detected  
207 among polymyxin-resistant strains. This suggests that  
208 the development of colistin resistance involves regu-  
209 latory mechanisms of gene expression. We identi-  
210 fied insertion mutations occurring downstream of  
211 *rpsL* in both Col-E1 and Col-E2. Mutations in  
212 *rpsL* are associated with resistance to streptomycin,  
213 kanamycin, and amikacin. Moreover, *rpsL* muta-  
214 tions were detected in many pathogens in the ES-  
215 KAPE group<sup>24</sup>. Hence, under antibiotic pressure,  
216 the alteration of *rpsL* expression might be the key  
217 factor that helps pathogens adapt to extreme condi-  
218 tions. We also reported a mutation in the upstream  
219 region of *oprD*, a porin that has been linked to many  
220 antibiotic-resistant strains, including carbapenem-  
221 resistant strains. Reduced expression/inactivation  
222 of OprD is a major carbapenem resistance mecha-  
223 nism<sup>25</sup>. Downregulation of *oprD* was also found  
224 in in vitro-induced ciprofloxacin-, ceftazidime-, and  
225 meropenem-resistant strains<sup>26,27</sup>. The genomic altera-  
226 tion in *oprD* found here might be linked to the altera-  
227 tion in the expression of OprD, which plays a part in  
228 colistin resistance in these strains. Indeed, the down-  
229 regulation of OprD can also affect colistin resistance


230 in *P. aeruginosa*<sup>28</sup>. Further investigation is needed to  
231 clarify the function of this *oprD* mutation in the de-  
232 velopment of colistin resistance. In addition to *oprD*,  
233 *oprH* and *oprF* are also important genes encoding the  
234 outer membrane proteins of *P. aeruginosa*. These muta-  
235 tions were detected, but no mutations were detected  
236 for these genes. OprH is thought to play an essential  
237 role in polymyxin resistance because it interacts with  
238 LPS and prevents polymyxin from binding to LPS<sup>29</sup>.  
239 Nevertheless, *P. aeruginosa* with an *oprH* deletion did  
240 not exhibit reduced susceptibility to polymyxin<sup>30</sup>. In  
241 contrast, the absence of OprF promoted biofilm for-  
242 mation and was linked to antibiotic resistance<sup>31</sup>.  
243 Efflux pumps contribute significantly to multidrug re-  
244 sistance in *P. aeruginosa*<sup>32</sup>. Mutations in the efflux  
245 pump regions usually result in increased expression of  
246 the pump, which lowers the antibiotic concentrations  
247 inside the cell. These mutations are typically found  
248 in the promoter region or upstream of genes<sup>33,34</sup>.  
249 Mutations in the efflux pump MexA induce antibi-  
250 otic resistance in *P. aeruginosa*<sup>35</sup>. The efflux pump  
251 MexXY/OprM has been known to contribute to the  
252 resistance of *P. aeruginosa* to colistin<sup>36</sup>. In one study,  
253 the knockout of MexXY-OprM increased the suscep-  
254 tibility of *P. aeruginosa* to cationic antimicrobial  
255 agents, while mutations in *mexX* and *mexY* did not



**Figure 2:** General statistics of the *P. aeruginosa* draft genome. (A) Length in base pairs of assembled contigs. (B) Cumulative contig length. (C) GC content over contigs.

256 change the sensitivity to polymyxin<sup>37</sup>. Our study re- 278  
 257 vealed an upstream mutation in *czcC\_1*, which has 279  
 258 transmembrane efflux transporter activity. This gene 280  
 259 is known to help *P. aeruginosa* resist cobalt-zinc- 281  
 260 cadmium<sup>38</sup>. Although the connection between these 282  
 261 heavy metals and colistin has been unclear, it has been 283  
 262 reported that the combination of colistin with zinc oxide 284  
 263 has a synergistic effect on *P. aeruginosa*<sup>39</sup>. The 285  
 264 combination of colistin and metals can be further in- 286  
 265 vestigated, which could help increase the effectiveness 287  
 266 of this last-resort antibiotic. 288  
 267 Similarly, the majority of variants appearing in the up- 289  
 268 stream and downstream regions suggest the role of 290  
 269 regulatory factors in ensuring survival of the pathogen 291  
 270 during the adaptation process. Previously, studies of 292  
 271 pathogen adaptation and evolution have focused pre- 293  
 272 dominantly on coding regions<sup>40,41</sup>. However, non- 294  
 273 coding regions (upstream, downstream, intergenic) 295  
 274 might contain elements that regulate the expression 296  
 275 of proteins and consequently determine virulence and 297  
 276 resistance phenotypes. Khademi et al. investigated 298  
 277 44 clonal lineages of *P. aeruginosa* and reported that 299

278 these types of mutations increase or decrease the tran- 279  
 279 scription of genes and are directly responsible for 280  
 280 the evolution of important pathogenic phenotypes<sup>42</sup>. 281  
 281 More importantly, intergenic mutations help essential 282  
 282 genes to become targets of evolution. 283  
 283 The development of antibiotic resistance is complex 284  
 284 and involves changes at the genomic and proteomic 285  
 285 levels<sup>43</sup>. These current characterizations of colistin- 286  
 286 resistant genomes further suggest that the develop- 287  
 287 ment of colistin resistance is a multifactorial process 288  
 288 involving both changes to ensure survival and muta- 289  
 289 tions that help individuals adapt to new environ- 290  
 290 ments. Further analysis of the resistomes and pro- 291  
 291 teomes of colistin-resistant strains might provide a 292  
 292 more comprehensive understanding of the develop- 293  
 293 ment of colistin resistance. 294  
 294 This study provided an understanding of how *P.* 295  
 295 *aeruginosa* with a fully antibiotic-susceptible profile 296  
 296 and thus a basic genetic background respond to col- 297  
 297 istin exposure. Limitations of the study include the 298  
 298 lack of repeated genomic sequencing of biological 299  
 299 replicates to ascertain genetic changes due to colistin



**Figure 3:** Genomic variant profiles of Col-E1 and Col-E2. (A) Number of variants observed in Col-E1 and Col-E2. (B) Overlapping SNPs between Col-E1 and Col-E2. (C) Overlapping INDELs between Col-E1 and Col-E2.

300 exposure and the lack of experimental evidence on the  
 301 effect of each genetic change on phenotypic changes.  
 302 Hence, further studies are required to clarify and improve  
 303 our findings. Mutagenesis and mutational studies  
 304 are essential to determine how these variants actually  
 305 affect gene expression in the colistin resistance  
 306 mechanism of *P. aeruginosa*.


307 **CONCLUSIONS**

308 Overall, this study was the first in Vietnam to assemble  
 309 the whole genome of *P. aeruginosa* ATCC 9027  
 310 and characterize the genomic variants in in vitro-  
 311 induced colistin-resistant strains. The analysis identified  
 312 notable mutations that were mostly found in non-  
 313 coding regions, indicating the possible gene expres-

314 sion regulation function of these mutations in the de-  
 315 velopment of the colistin resistance phenotype. These  
 316 variants could serve as potential colistin resistance  
 317 markers for quick diagnostic tests. Mutagenesis and  
 318 mutational studies should be further performed to  
 319 understand the role of noncoding regions in the adap-  
 320 tation and evolution of colistin-resistant *P. aerugi-*  
 321 *nosa*.

322 **LIST OF ABBREVIATIONS**

323 Whole genome sequencing (WGS), World Health  
 324 Organization (WHO), multidrug-resistant (MDR),  
 325 extensively drug-resistant (XDR), lipopolysaccharide  
 326 (LPS), minimum inhibitory concentration (MIC),  
 327 tryptic soya broth (TSB), paired-end (PE), single



**Figure 4:** Functional annotation of the genomic variants of Col-E1. (A) Functional effects and (B) region-based annotation of SNPs. (C) Functional effects and (D) region-based annotation of INDELS.

328 nucleotide polymorphism (SNP), insertion–deletion  
329 (INDEL)

330 **COMPETING INTERESTS**

331 The authors declare that they have no competing in-  
332 terests.

333 **ACKNOWLEDGEMENTS**


334 This research was partially funded by the Vietnam Na-  
335 tional Foundation for Science and Technology Devel-  
336 opment (NAFOSTED) under grant number 108.04-  
337 2018.08.

338 **REFERENCES**

339 1. World Health Organization (WHO) [Internet]. [cited 2024 May  
340 10]; Available from: <https://www.who.int/>.  
341 2. Azimi L, Lari AR. Colistin-resistant *Pseudomonas aeruginosa*  
342 clinical strains with defective biofilm formation. *GMS Hyg In-*  
343 *fect Control*. 2019 Oct 10;14:Doc12;.  
344 3. Jeannot K, Hagart K, Dortet L, Kostrzewa M, Filloux A,  
345 Plesiat P, et al. Detection of Colistin Resistance in *Pseu-*  
346 *domonas aeruginosa* Using the MALDIx Test on the Rou-  
347 tine MALDI Biotyper Sirius Mass Spectrometer. *Front Micro-*  
348 *biol*. 2021;12:725383;PMID: 34531843. Available from: <https://doi.org/10.3389/fmicb.2021.725383>.  
349 4. Bialvaei AZ, Samadi Kafil H. Colistin, mechanisms and pre-  
350 valence of resistance. *Curr Med Res Opin*. 2015 Apr;31(4):707-  
351 21;PMID: 25697677. Available from: <https://doi.org/10.1185/>

353 03007995.2015.1018989.  
354 5. Biswas S, Brunel JM, Dubus JC, Reynaud-Gaubert M, Rolain  
355 JM. Colistin: an update on the antibiotic of the 21st cen-  
356 tury. *Expert Rev Anti Infect Ther*. 2012 Aug;10(8):917-34;PMID:  
357 23030331. Available from: <https://doi.org/10.1586/eri.12.78>.  
358 6. Kaye KS, Pogue JM, Tran TB, Nation RL, Li J. Agents of Last  
359 Resort: Polymyxin Resistance. *Infect Dis Clin North Am*. 2016  
360 Jun;30(2):391-414;PMID: 27208765. Available from: <https://doi.org/10.1016/j.idc.2016.02.005>.  
361 7. Poirel L, Jayol A, Nordmann P. Polymyxins: Antibacterial Ac-  
362 tivity, Susceptibility Testing, and Resistance Mechanisms En-  
363 coded by Plasmids or Chromosomes. *Clin Microbiol Rev*. 2017  
364 Apr;30(2):557-96;PMID: 28275006. Available from: <https://doi.org/10.1128/CMR.00064-16>.  
365 8. Ding Y, Hao J, Xiao W, Ye C, Xiao X, Jian C, et al. Role of efflux  
366 pumps, their inhibitors, and regulators in colistin resistance.  
367 *Front Microbiol*. 2023 Aug 4;14:1207441;PMID: 37601369.  
368 Available from: <https://doi.org/10.3389/fmicb.2023.1207441>.  
369 9. Campos MA, Vargas MA, Regueiro V, Llompart CM, Alberti  
370 S, Bengoechea JA. Capsule polysaccharide mediates bacte-  
371 rial resistance to antimicrobial peptides. *Infect Immun*. 2004  
372 Dec;72(12):7107-14;PMID: 15557634. Available from: <https://doi.org/10.1128/IAI.72.12.7107-7114.2004>.  
373 10. Martin M. Cutadapt removes adapter sequences from high-  
374 throughput sequencing reads. *EMBnet journal*. 2011 May  
375 2;17(1):10-2; Available from: <https://doi.org/10.14806/ej.17.1.200>.  
376 11. Babraham Bioinformatics - FastQC A Quality Control tool for  
377 High Throughput Sequence Data [Internet]. [cited 2024 May  
378 15]; Available from: <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>.  
379 12. Wick RR, Judd LM, Gorrie CL, Holt KE. Unicycler: Resolving  
380  
381  
382  
383  
384





**Figure 5:** Functional annotation of the genomic variants of Col-E2. (A) Functional effects and (B) region-based annotation of SNPs. (C) Functional effects and (D) region-based annotation of INDELS.

385 bacterial genome assemblies from short and long sequencing  
 386 reads. *PLOS Comput. Biol.*. 2017 Jun 8;13(6):e1005595;PMID:  
 387 28594827. Available from: <https://doi.org/10.1371/journal.pcbi.1005595>.  
 388  
 389 13. ablab/quast [Internet]. Ex Center for Algorithmic Biotechnol-  
 390 ogy; 2024 [cited 2024 May 17]; Available from: <https://github.com/ablab/quast>.  
 391  
 392 14. Prokka: rapid prokaryotic genome annotation | Bioinformatic-  
 393 s | Oxford Academic [Internet]. [cited 2024 May 15]; Available  
 394 from: <https://academic.oup.com/bioinformatics/article/30/14/2068/2390517>.  
 395  
 396 15. Langmead B, Salzberg SL. Fast gapped-read alignment  
 397 with Bowtie 2. *Nat Methods*. 2012 Mar 4;9(4):357-9;PMID:  
 398 22388286. Available from: <https://doi.org/10.1038/nmeth.1923>.  
 399  
 400 16. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al.  
 401 The Sequence Alignment/Map format and SAMtools. *Bioinformatic-*  
 402 *ics*. 2009 Aug 15;25(16):2078-9;PMID: 19505943. Available  
 403 from: <https://doi.org/10.1093/bioinformatics/btp352>.  
 404  
 405 17. García-Alcalde F, Okonechnikov K, Carbonell J, Cruz LM,  
 406 Götz S, Tarazona S, et al. Qualimap: evaluating next-  
 407 generation sequencing alignment data. *Bioinformatics*. 2012  
 408 Oct 15;28(20):2678-9;PMID: 22914218. Available from: <https://doi.org/10.1093/bioinformatics/bts503>.  
 409  
 410 18. Cingolani P, Platts A, Wang LL, Coon M, Nguyen T, Wang L, et  
 411 al. A program for annotating and predicting the effects of single  
 412 nucleotide polymorphisms, SnpEff. *Fly (Austin)*. 2012 Apr  
 413 1;6(2):80-92;PMID: 22728672. Available from: <https://doi.org/10.4161/fly.19695>.  
 414  
 415 19. Aminov RI. The role of antibiotics and antibiotic resistance  
 416 in nature. *Environ Microbiol*. 2009 Dec;11(12):2970-88;PMID:  
 19601960. Available from: <https://doi.org/10.1111/j.1462-2920.2009.01972.x>.  
 417  
 418 20. Blázquez J, Couce A, Rodríguez-Beltrán J, Rodríguez-Rojas A.  
 419 Antimicrobials as promoters of genetic variation. *Curr Opin*  
 420 *Microbiol*. 2012 Oct;15(5):561-9;PMID: 22890188. Available  
 421 from: <https://doi.org/10.1016/j.mib.2012.07.007>.  
 422  
 423 21. López E, Elez M, Matic I, Blázquez J. Antibiotic-mediated re-  
 424 combination: ciprofloxacin stimulates SOS-independent re-  
 425 combination of divergent sequences in *Escherichia coli*. *Mol*  
 426 *Microbiol*. 2007 Apr;64(1):83-93;PMID: 17376074. Available  
 427 from: <https://doi.org/10.1111/j.1365-2958.2007.05642.x>.  
 428  
 429 22. Olaitan AO, Morand S, Rolain JM. Mechanisms of polymyxin  
 430 resistance: acquired and intrinsic resistance in bacteria. *Front*  
 431 *Microbiol* [Internet]. 2014 Nov 26 [cited 2024 May 17];5;PMID:  
 432 25505462. Available from: <https://doi.org/10.3389/fmicb.2014.00643>.  
 433  
 434 23. Lee JY, Ko KS. Mutations and expression of PmrAB and  
 435 PhoPQ related with colistin resistance in *Pseudomonas aeruginosa*  
 436 clinical isolates. *Diagn Microbiol Infect Dis*. 2014 Mar  
 437 1;78(3):271-6;PMID: 24412662. Available from: <https://doi.org/10.1016/j.diagmicrobio.2013.11.027>.  
 438  
 439 24. Ghosh A, N. S, Saha S. Survey of drug resistance associated  
 440 gene mutations in *Mycobacterium tuberculosis*, ESKAPE and  
 441 other bacterial species. *Sci Rep*. 2020 Jun 2;10:8957;PMID:  
 442 32488120. Available from: <https://doi.org/10.1038/s41598-020-65766-8>.  
 443  
 444 25. Courtois N, Caspar Y, Maurin M. Phenotypic and genetic re-  
 445 sistance traits of *Pseudomonas aeruginosa* strains infecting  
 446 cystic fibrosis patients: A French cohort study. *Int J Antimicrob*  
 447 *Agents*. 2018 Sep;52(3):358-64;PMID: 29775685. Avail-  
 448 able from: <https://doi.org/10.1016/j.ijantimicag.2018.05.008>.  
 449  
 450 26. Huynh TQ, Tran NBV, Pham TTV, Le VBT, Truong TP, Huynh VA,  
 451 et al. Adaptive response of *Pseudomonas aeruginosa* under

449 serial ciprofloxacin exposure. *Microbiology (Reading)*. 2024  
 450 Apr;170(3):001443;PMID: 38568202. Available from: <https://doi.org/10.1099/mic.0.001443>.  
 451

452 27. Ngo HL, Huynh TQ, Tran NBV, Nguyen NHB, Tong TH, Trinh  
 453 TTL, et al. Proteomic analysis of ceftazidime and meropenem-  
 454 exposed *Pseudomonas aeruginosa* ATCC 9027. *Proteome Sci*.  
 455 2023 Sep 28;21:15;PMID: 37770917. Available from: <https://doi.org/10.1186/s12953-023-00217-6>.  
 456

457 28. Muller C, Plésiat P, Jeannot K. A two-component regu-  
 458 latory system interconnects resistance to polymyxins,  
 459 aminoglycosides, fluoroquinolones, and  $\beta$ -lactams in  
 460 *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*.  
 461 2011 Mar;55(3):1211-21;PMID: 21149619. Available from:  
 462 <https://doi.org/10.1128/AAC.01252-10>.  
 463

464 29. Edrington TC, Kintz E, Goldberg JB, Tamm LK. Structural ba-  
 465 sis for the interaction of lipopolysaccharide with outer mem-  
 466 brane protein H (OprH) from *Pseudomonas aeruginosa*. *J Biol*  
 467 *Chem*. 2011 Nov 11;286(45):39211-23;PMID: 21865172. Avail-  
 468 able from: <https://doi.org/10.1074/jbc.M111.280933>.  
 469

470 30. Macfarlane ELA, Kwasnicka A, Hancock REW. Role of *Pseu-*  
 471 *domonas aeruginosa* PhoP-PhoQ in resistance to antimicro-  
 472 bial cationic peptides and aminoglycosides. *Microbiology*.  
 473 2000;146(10):2543-54;PMID: 11021929. Available from: <https://doi.org/10.1099/00221287-146-10-2543>.  
 474

475 31. Bouffartigues E, Moscoso JA, Duchesne R, Rosay T, Fito-  
 476 Boncompte L, Gicquel G, et al. The absence of the *Pseu-*  
 477 *domonas aeruginosa* OprF protein leads to increased biofilm  
 478 formation through variation in c-di-GMP level. *Front Micro-*  
 479 *biol*. 2015;6:630;PMID: 26157434. Available from: <https://doi.org/10.3389/fmicb.2015.00630>.  
 480

481 32. Bhardwaj AK, Mohanty P. Bacterial efflux pumps involved in  
 482 multidrug resistance and their inhibitors: rejuvenating the an-  
 483 timicrobial chemotherapy. *Recent Pat Antiinfect Drug Discov*.  
 484 2012 Apr;7(1):73-89;PMID: 22353004. Available from: <https://doi.org/10.2174/157489112799829710>.  
 485

486 33. Fernández L, Hancock REW. Adaptive and mutational resis-  
 487 tance: role of porins and efflux pumps in drug resistance. *Clin*  
 488 *Microbiol Rev*. 2012 Oct;25(4):661-81;PMID: 23034325. Avail-  
 489 able from: <https://doi.org/10.1128/CMR.00043-12>.  
 490

491 34. Baylay AJ, Ivens A, Piddock LJV. A novel gene amplifica-  
 492 tion causes upregulation of the PatAB ABC transporter and  
 493 fluoroquinolone resistance in *Streptococcus pneumoniae*.  
 494 *Antimicrob Agents Chemother*. 2015;59(6):3098-108;PMID:  
 495 25779578. Available from: <https://doi.org/10.1128/AAC.04858-14>.  
 496

497 35. Nehme D, Poole K. Interaction of the MexA and MexB Compo-  
 498 nents of the MexAB-OprM Multidrug Efflux System of *Pseu-*  
 499 *domonas aeruginosa*: Identification of MexA Extragenic Sup-  
 500 pressors of a T578I Mutation in MexB. *Antimicrob Agents*  
 501 *Chemother*. 2005 Oct;49(10):4375-8;PMID: 16189126. Avail-  
 502 able from: <https://doi.org/10.1128/AAC.49.10.4375-4378.2005>.  
 503

504 36. Puja H, Bolard A, Nogués A, Plésiat P, Jeannot K. The Ef-  
 505 flux Pump MexXY/OprM Contributes to the Tolerance and  
 506 Acquired Resistance of *Pseudomonas aeruginosa* to Colistin.  
 507 *Antimicrob Agents Chemother*. 2020 Mar 24;64(4):e02033-  
 508 19;PMID: 31964794. Available from: <https://doi.org/10.1128/AAC.02033-19>.  
 509

510 37. Liang Y, Li J, Xu Y, He Y, Jiang B, Wu C, et al. Genomic varia-  
 511 tions in polymyxin-resistant *Pseudomonas aeruginosa* clinical  
 512 isolates and their effects on polymyxin resistance. *Braz J Mi-*  
 513 *crobiol*. 2023 Mar 17;54(2):655-64;PMID: 36930447. Available  
 514 from: <https://doi.org/10.1007/s42770-023-00933-3>.  
 515

516 38. czcC\_1 - Cobalt-zinc-cadmium resistance protein CzcC - *Pseu-*  
 517 *domonas aeruginosa* | Publications | UniProtKB | UniProt  
 518 [Internet]. [cited 2024 Jun 6]; Available from: <https://www.uniprot.org/uniprotkb/A0A9P1R6A7/publications>.  
 519

520 39. Fadwa AO, Alkoblan DK, Mateen A, Albarag AM. Synergistic ef-  
 521 fects of zinc oxide nanoparticles and various antibiotics com-  
 522 bination against *Pseudomonas aeruginosa* clinically isolated  
 523 bacterial strains. *Saudi J Biol Sci*. 2021 Jan;28(1):928-35;PMID:  
 524 33424384. Available from: <https://doi.org/10.1016/j.sjbs.2020.09.064>.  
 525

526 40. Marvig RL, Sommer LM, Molin S, Johansen HK. Convergent  
 527 evolution and adaptation of *Pseudomonas aeruginosa* within  
 528 patients with cystic fibrosis. *Nat Genet*. 2015 Jan;47(1):57-  
 529 64;PMID: 25401299. Available from: <https://doi.org/10.1038/ng.3148>.  
 530

531 41. Klemm EJ, Gkrania-Klotsas E, Hadfield J, Forbester JL, Harris  
 532 SR, Hale C, et al. Emergence of host-adapted *Salmonella* En-  
 533 teritidis through rapid evolution in an immunocompromised  
 534 host. *Nat Microbiol*. 2016 Jan 25;1(3):1-6; Available from: <https://doi.org/10.1038/nmicrobiol.2015.23>.  
 535

536 42. Khademi SMH, Sazinas P, Jelsbak L. Within-Host Adaptation  
 537 Mediated by Intergenic Evolution in *Pseudomonas aerug-*  
 538 *inosa*. *Genome Biol Evol*. 2019 Apr 13;11(5):1385-97;PMID:  
 539 30980662. Available from: <https://doi.org/10.1093/gbe/evz083>.  
 540

541 43. Huynh TQ, Tran VN, Thai VC, Nguyen HA, Nguyen NTG, Tran  
 542 MK, et al. Genomic alterations involved in fluoroquinolone re-  
 543 sistance development in *Staphylococcus aureus*. *PLOS ONE*.  
 544 2023 Jul 26;18(7):e0287973;PMID: 37494330. Available from:  
 545 <https://doi.org/10.1371/journal.pone.0287973>.  
 546